Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
Mazen Noureddin, Stephen A. Harrison, Rohit Loomba, Naim Alkhouri, Naga Chalasani, Muhammad Y. Sheikh, Shaheen Tomah, Julio Gutiérrez, Silvia Urbina, John J. Suschak, Randy A. Brown, Ozioma Odili, Jay Yang, Stephine Keeton, Guy Neff, Edward Mena, M. Scot Roberts, Sarah Browne, M. Scott Harris
Topics & Concepts
MedicineSteatohepatitisPlaceboInternal medicineGastroenterologyNonalcoholic steatohepatitisPhases of clinical researchClinical trialPhase (matter)Fatty liverLiver Disease Diagnosis and TreatmentDiet and metabolism studiesDiet, Metabolism, and Disease